Everand Logo

Welcome to Everand!

  • STAT

    Plastic tubes can’t save the lives of liver failure patients, and a biotech’s stock price plummets

    Another effort by Vital Therapies to transform plastic tubes into a lifesaving artificial liver ended in disappointment.
    by Adam Feuerstein Sep 12, 2018 1 minute

    Another effort by Vital Therapies () to transform into a lifesaving artificial liver ended in disappointment Wednesday. And after this latest setback, the

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About GLP-1 Spending, Biosimilar Patient Costs, And More
    Spending on GLP-1 drugs like Ozempic and Wegovy ballooned last year and they're set to cost the U.S. health care system and the federal government still more.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
    The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
    Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

    Related Books & Audiobooks